Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation

被引:94
作者
Penning-van Beest, FJA
van Meegen, E
Rosendaal, FR
Stricker, BHC
机构
[1] Erasmus Univ, Med Ctr, Dept Internal Med, Pharmacoepidemiol Unit, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, Pharmacoepidemiol Unit, NL-3000 CA Rotterdam, Netherlands
[3] Red Cross Anticoagulat Clin, The Hague, Netherlands
[4] Leiden Univ, Ctr Hemostasis & Thrombosis Res, Dept Clin Epidemiol, Med Ctr, The Hague, Netherlands
[5] Inspectorate Hlth Care, Drug Safety Unit, The Hague, Netherlands
关键词
overanticoagulation; coumarin anticoagulants; incidence; comorbidity; characteristics of therapy;
D O I
10.1055/s-0037-1616088
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of hemorrhage when using coumarin anticoagulants sharply increases when the International Normalised Ratio (INR) is greater than or equal to6.0. We performed a prospective cohort study with a nested case-control design among 17,056 outpatients of an anticoagulation clinic to determine the incidence of overanticoagulation and to study the association between overanticoagulation and characteristics of anticoagulant therapy and comorbidity. The incidence rate of an INR greater than or equal to6.0 was 7.8 per 10,000 treatment days in prevalent users on the starting date and 22.5 per 10,000 treatment days in incident users during the study period. 300 cases with an INR greater than or equal to6.0 were compared with 302 randomly selected matched controls with an INR within the target zone. Patients on acenocoumarol had an increased risk of an INR greater than or equal to6.0 compared to patients on phenprocoumon. Regarding comorbidity, impaired liver function, congestive heart failure, diarrhea and fever were risk factors for overanticoagulation. Increased monitoring of INR values if risk factors are present or avoidance of risk factors could prevent excess anticoagulation and potential bleeding complications.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 29 条
[1]   EFFECT OF WEIGHT-LOSS ON COAGULATION FACTOR-VII AND FACTOR-X [J].
BARON, JA ;
MANN, J ;
STUKEL, T .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (08) :519-522
[2]  
BREED WPM, 1969, ACTA MED SCAND, V186, P283
[3]  
Brigden ML, 1998, AM J HEMATOL, V59, P22, DOI 10.1002/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.3.CO
[4]  
2-J
[5]  
*BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P374
[6]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[7]  
CARON J, 1996, MEYLERS SIDE EFFECTS, P1008
[8]   ANTICOAGULATION INSTABILITY WITH LIFE-THREATENING COMPLICATION AFTER DIETARY MODIFICATION [J].
CHOW, WH ;
CHOW, TC ;
TSE, TM ;
TAI, YT ;
LEE, WT .
POSTGRADUATE MEDICAL JOURNAL, 1990, 66 (780) :855-857
[9]  
Cushman M, 1996, AM J EPIDEMIOL, V143, P665
[10]   POPULATION CORRELATES OF PLASMA-FIBRINOGEN AND FACTOR-VII, PUTATIVE CARDIOVASCULAR RISK-FACTORS [J].
FOLSOM, AR ;
WU, KK ;
DAVIS, CE ;
CONLAN, MG ;
SORLIE, PD ;
SZKLO, M .
ATHEROSCLEROSIS, 1991, 91 (03) :191-205